You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
天宇股份(300702.SZ):厄貝沙坦氫氯噻嗪片獲得藥品註冊證書
格隆匯 03-31 19:20

格隆匯3月31日丨天宇股份(300702.SZ)公佈,公司全資子公司諾得藥業於近日收到國家藥監局核准簽發的關於厄貝沙坦氫氯噻嗪片的《藥品註冊證書》。厄貝沙坦氫氯噻嗪片獲得國家藥監局批件後即可在境內生產、銷售。

厄貝沙坦氫氯噻嗪片主要用於治療原發性高血壓,最早於1997年9月由賽諾菲公司研發上市,商品名為“AVALIDE®”;於2003年6月在中國上市,商品名為“安博諾®”。根據國家藥監局網站數據查詢,截至公吿日同規格厄貝沙坦氫氯噻嗪片國內生產商另有安徽環球藥業股份有限公司、南京正大天晴製藥有限公司及浙江華海藥業股份有限公司等13家企業。據統計,2020年厄貝沙坦氫氯噻嗪片在國內樣本醫院(包括城市公立醫院,城市社區醫院,縣級公立醫院,鄉鎮衞生院)和城市實體藥店的銷售額約人民幣18.76億元(數據來源於米內網)。

諾得藥業厄貝沙坦氫氯噻嗪片於2020年12月獲得國家藥監局受理,目前公司及子公司累計投入費用約1344.71萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account